C-terminal telopeptide
In bone physiology, the C-terminal telopeptide (known by the acronym CTX) is a serum biomarker used to measure the rate of bone turnover. It can be useful in assisting clinicians to determine a patient's nonsurgical treatment response as well as evaluate a patient's risk of developing complications during healing following surgical intervention.[1]
Bisphosphonate-associated osteonecrosis of the jaw
In the early 2000s, a link between bisphosphonate use and impaired wound healing following tooth extractions was noted.[2][3]
References
- ^ Marx, RE, et al. Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment, J Oral Maxillofac Surg 2007;65:2397-2410
- ^ Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115
- ^ Ruggerio SL, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527